Emergence of *Escherichia coli* producing OXA-48-like carbapenemase in a patient with percutaneous transhepatic biliary drainage

Carbapenemase-producing Enterobacteriaceae are often multidrug-resistant (MDR) and pose serious problems for clinical treatment and infection control. Here, we report the first isolation of *Escherichia coli* producing OXA-48-like carbapenemase from a patient after percutaneous transhepatic biliary drainage (PTBD). The PTBD surgery was performed in India, and the bacteria were isolated at Teikyo University Hospital in Tokyo, Japan.

A 66-year-old man living in Kuwait was admitted to hospital in Mumbai, India, complaining of jaundice. He was diagnosed with intrahepatic cholangiocarcinoma and received PTBD to improve jaundice. He subsequently received anti-cancer chemotherapy in Kuwait and was later admitted to our hospital, Teikyo University Hospital, for further treatment. Upon admission to our hospital, the patient was diagnosed with obstructive jaundice and drug-resistant bacteria were detected in the bacterial culture from the tip of the PTBD tube. Ampicillin/sulbactam and amikacin combination therapy was used as infection prevention for only 1 day at the time of the PTBD exchange surgery because there were no symptoms of infection or inflammation. Subsequently, the patient received anti-cancer chemotherapy and was discharged after removal of the PTBD device.

The PTBD drain and peritoneal drain were collected for screening. To screen for extended-spectrum beta-lactamase (ESBL)-producing bacteria and carbapenem-resistant organisms (CRO), samples were cultured on CHROMagar ESBL/MDRA (Kanto Chemical, Tokyo, Japan) and BTB agar (Eiken Chemical, Tokyo, Japan) with a piperacillin/tazobactam (PIPC/TAZ, 100/10 \( \mu \)g) disc (Becton Dickinson, Franklin Lakes, NJ, USA) or an imipenem (10 \( \mu \)g) disc (Becton Dickinson, Franklin Lakes, NJ, USA). Isolates were identified with a MALDI biotyper (Bruker Daltonics, Billerica, MA, USA) and Vitek MS system (bioMérieux, Marcy l’Etoile, France). Susceptibility was defined according to breakpoints listed in the Clinical and Laboratory Standards Institute (CLSI) guidelines M100-S24. Testing was performed with a MicroScan WalkAway (Beckman Coulter, Brea, CA, USA).

A total of seven Gram-negative rod (GNR) species and three Gram-positive cocci (GPC) species were collected from the patient’s peritoneal drain and PTBD drain (Table I). Of the GNR species, four were identified as *Escherichia coli* and three were identified as *Klebsiella* species. Among the GPC species, *Enterococcus casseliflavus* and *Enterococcus faecalis* were identified.

### Table I
Summary of bacterial isolates.

| Sample       | Gram stain | Species                        | Isolate number |
|--------------|------------|--------------------------------|----------------|
| Peritoneal drain | GNR        | Aeromonas hydrophila            | 1              |
|              |            | *Escherichia coli*              | 2              |
|              |            | *Klebsiella aerogenes*          | 1              |
|              |            | *Klebsiella pneumoniae*         | 1              |
|              |            | *Pseudomonas aeruginosa*        | 1              |
|              | GPC        | *Enterococcus casseliflavus*    | 1              |
|              |            | *Enterococcus faecalis*         | 1              |
|              |            | *Streptococcus viridans*        | 1              |
| PTBD drain   | GNR        | *Escherichia coli*              | 3              |
|              |            | *Klebsiella aerogenes*          | 2              |
|              |            | *Klebsiella oxytoca*            | 1              |
|              |            | *Klebsiella pneumoniae*         | 3              |
|              |            | *Pseudomonas aeruginosa*        | 2              |
|              |            | *Stenotrophomonas maltophilia*  | 1              |
|              | GPC        | *Enterococcus casseliflavus*    | 1              |
|              |            | *Enterococcus faecalis*         | 2              |
|              |            | *Streptococcus viridans*        | 2              |

GNR, Gram-negative rods; GPC, Gram-positive cocci; PTBD, percutaneous transhepatic biliary drainage.

https://doi.org/10.1016/j.infpip.2019.100008
2590-0889/ © 2019 The Authors. Published by Elsevier Ltd on behalf of The Healthcare Infection Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Aeromonas hydrophila, E. coli, Klebsiella aerogenes, K. pneumoniae and Pseudomonas aeruginosa were isolated from the peritoneal drain, and E. coli, K. aerogenes, K. oxytoca, K. pneumoniae, P. aeruginosa and Stentrophomonas maltophilia were isolated from the PTBD drain. The GPC species Enterococcus casseliflavus, E. faecalis and a viridans streptococcus were isolated from both the peritoneal and PTBD drains.

Four of the 7 GNR species were PIPC/TAZ resistant; E. coli, P. aeruginosa and S. maltophilia showed an MDR phenotype. The antibiotic susceptibility profiles of these isolates are shown in Table II, along with the results of testing for carbapenemase and ESBL genes. Multiplex polymerase chain reaction (PCR) with a Cica Geneus genotype detection kit (Kanto Chemical, Tokyo, Japan) was used to identify the carbapenemase and ESBL genes.

Table II
Susceptibility profiles of multidrug-resistant Gram-negative bacteria

| Species                  | E. coli | S. maltophilia | P. aeruginosa | A. hydrophila |
|--------------------------|---------|----------------|---------------|---------------|
| **Carbapenemase**        |         |                |               |               |
| OXA-48                   |         |                |               |               |
| **Extended-spectrum β-lactamase** |         |                |               |               |
| CTX-M-1, TEM             |         |                |               |               |

Antimicrobial agents

**Penicillins**
- Piperacillin: >64, >64, >64, 64
- Ampicillin/sulbactam: >16, >16, >16, >16
- Amoxicillin/clavulanic acid: >16, >16, >16, 16
- Piperacillin/tazobactam: >64, >64, >64, 64

**Cephalosporins**
- Cefazolin: >16, >16, >16, >16
- Cefotiam: >16, >16, >16, >16
- Cefotaxim: >2, >2, >2, >2
- Ceftazidime: >16, >16, >16, >16
- Ceftriaxone: >2, >2, >2, >2
- Cefepime: >16, >16, 16, 2
- Cefozopran: >16, >16, >16, 4
- Cefmetazole: >32, >32, >32, >32
- Cefpodoxime: >4, >4, >4, >4
- Cefcapene: >2, >2, >2, >2
- Flomoxef: >32, >32, >32, 32
- Cephoperazone/sulbactam: >32, >32, >32, >32

**Carbapenems**
- Doripenem: 1, ND, 1, 1
- Imipenem: 2, >8, 1, 1
- Meropenem: 1, >8, 1, 1
- Monobactam
- Aztreonam: >16, >16, 16, 4

**Fluoroquinolones**
- Ciprofloxacin: >2, 2, >2, 1
- Levofloxacin: >4, 1, >4, 0.5
- Sitafloxacin: >2, 1, >2, 1

**Aminoglycosides**
- Gentamicin: 2, 8, 4, 2
- Tobramycin: 4, 8, 4, 4
- Amikacin: 4, >32, 8, 4

**Tetracycline**
- Minocycline: >8, 2, >8, 2

**Polymyxin**
- Colistin: 2, ND, 2, 2

**Other**
- Fosfomycin: 4, >16, >16, 16
- Trimethoprim/Sulfamethoxazole: >2, 2, >2, 2

Minimum inhibitory concentration (mg/L) values in bold represent resistant or non-susceptible strains. ND, not determined.
been isolated from blood cultures. Microorganisms including Enterobacteriaceae, P. aeruginosa, Enterococcus spp. and Candida spp., have been isolated from infected bile. Aeromonas spp. were isolated from a patient with sepsis who had transhepatic biliary devices [2]. However, these isolates were not reported to be drug-resistant. In the present study, we isolated a number of MDR GNR species from an infection associated with a transhepatic biliary drainage device, including OXA-48-producing E. coli and carbapenem-resistant S. maltophilia. To our knowledge, CRO and CPO (carbapenemase-producing organism) infections associated with PTBD devices have not been reported previously. S. maltophilia and Aeromonas spp. have intrinsic and inducible carbapenemases [3]. Such inducible CPOs should be further investigated to help prevent and control infections associated with transhepatic biliary drainage devices.

OXA-48-producing E. coli has been detected previously in patients hospitalised in India. For example, OXA-48-like-producing E. coli was isolated from patients who were transferred from India to France in 2011 [5]. Patients hospitalised in India are therefore at risk of infection or colonisation with OXA-48-producing Enterobacteriaceae [4]. OXA-48-like-producing Enterobacteriaceae have also spread throughout Turkey, Mediterranean countries and South Asia. The first OXA-48-producing Enterobacteriaceae reported in Japan were OXA-48-producing K. pneumoniae and E. coli, isolated from a patient with a medical history in Southeast Asia [6]. The OXA-48-like-producing E. coli isolates found in Japan and France, including those in the present study, were not resistant to carbapenems but were resistant to PIPC/TAZ [5,6]. Therefore, PIPC/TAZ may be useful for detecting carbapenem-sensitive CPOs. It is vital to continue to test for OXA-48-producing Enterobacteriaceae in hospitalised patients.

The results presented herein suggest that a medical history in India may be related to infection with a wide variety of MDR organisms. To reduce the spread of MDR organisms to low-prevalence countries like Japan, screening of all patients with a history of hospitalisation and travel abroad may be necessary. We suggest that medical staff consider contacting outpatients colonised with CPOs to help prevent the spread of MDR organisms.

Acknowledgements

We thank Drs. Ueda, Nagakawa and Ubagai in the department of microbiology and immunology in Teikyo University School of Medicine for helpful discussions and technical assistance. Informed consent was obtained according to the guidelines at Teikyo University Hospital.

Declarations

Funding

This work was supported by the Japan Society for the Promotion of Science (JSPS), Japan [KAKENHI 24591490 and 17K10032 to Y.O., and 18K10030 to S.N.] and the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [Private University Research Branding Project].

Competing Interests

No conflicts of interest associated with this manuscript.

Ethical approval

Not required.

References

[1] Szabo S, Mendelson MH, Mitty HA, Bruckner HW, Hirschman SZ. Infections associated with transhepatic biliary drainage devices. Am J Med 1987;82:921–6.
[2] Doudier B, Imbert G, Vilton V, Kahn M, La Scola B. Aeromonas septicaemia: an uncommon complication following placement of transhepatic biliary drainage devices in Europe. J Hosp Infect 2006;62:115–6. https://doi.org/10.1016/j.jhin.2005.05.004.
[3] Queenan AM, Bush K. Carbapenemases: the Versatile -Lactamases. Clin Microbiol Rev 2007;20:440–58. https://doi.org/10.1128/CMR.00001-07.
[4] Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. Early Dissemination of NDM-1- and OXA-181-Producing Enterobacteriaceae in Indian Hospitals: Report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother 2011;55:1274–8. https://doi.org/10.1128/AAC.01497-10.
[5] Potron A, Rondinaud E, Poirel L, Belmonte O, Boyer S, Camiade S, et al. Genetic and biochemical characterisation of OXA-232, a carbapenem-hydrolysing class D β-lactamase from Enterobacteriaceae. Int J Antimicrob Agents 2013;41:325–9. https://doi.org/10.1016/j.ijantimicag.2012.11.007.
[6] Nagano N, Endoh Y, Nagano Y, Toyama M, Matsui M, Shibayama K, et al. First report of OXA-48 carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Japan from a patient returned from Southeast Asia. Jpn J Infect Dis 2013;66:79–81.

Satoshi Nishida*, Miwa Asahara, Kentaro Nemoto, Shinobu Ishigaki, Taiji Furukawa, Keiji Sano, Yasuo Ono

*Department of Microbiology and Immunology, Teikyo University School of Medicine, Itabashi, Tokyo, Japan

**Department of Laboratory Medicine, Teikyo University Hospital, Itabashi, Tokyo, Japan

†Department of Surgery, Teikyo University School of Medicine, Itabashi, Tokyo, Japan

* Address Correspondence to: Satoshi Nishida, Department of Microbiology and Immunology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8605, Japan. Tel.: +81 3 3964 3632; fax: +81 3 5375 5284. E-mail address: nishida@med.teikyo-u.ac.jp (S. Nishida).

Available online 3 July 2019